Predicate Devices

Reference Devices

AI/ML (Artificial Intelligence / Machine Learning)

No
The summary describes a qualitative fluorescence in situ hybridization assay with manual interpretation using fluorescence microscopy. There is no mention of automated image analysis, pattern recognition, or any other technology that would typically involve AI/ML. The performance studies focus on traditional analytical and clinical metrics, not on the training or validation of an AI/ML model.

Therapeutic

No.
The device is an in-vitro diagnostic assay intended for the detection of a specific mRNA marker to aid in the diagnosis of methicillin-resistant S. aureus (MRSA) infections; it does not directly treat or prevent a disease.

Diagnostic

Yes

Explanation: The intended use of the device is to aid in the detection of mecA mRNA from methicillin-resistant S. aureus (MRSA) from patient positive blood cultures, providing information for diagnosis, which is a characteristic of a diagnostic device.

SaMD (Software as a Medical Device)

No

The device description explicitly lists physical components such as reagents, a microscope slide, and coverslip mounting media, indicating it is a hardware-based assay kit.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

Intended Use: The intended use explicitly states it's a "qualitative nucleic acid fluorescence in situ hybridization assay intended for the detection of mecA mRNA on smears from blood cultures... as an aid in the detection of mecA mRNA from methicillin-resistant S. aureus (MRSA) from patient positive blood cultures." This clearly indicates it's used to test samples taken from the human body (blood cultures) to provide information about a patient's health status (presence of mecA mRNA indicating MRSA).
Device Description: The description details a kit with reagents and a slide for performing a test on a biological sample (aliquot of blood culture).
Anatomical Site: The test is performed on "Blood cultures," which are samples derived from the human body.
Intended User / Care Setting: The results are intended to be used "in conjunction with other laboratory tests and clinical data available to the clinician," indicating its use in a healthcare or laboratory setting for diagnostic purposes.
Performance Studies: The document includes detailed descriptions of both bench testing and clinical studies, which are standard requirements for demonstrating the performance and validity of an IVD.
Key Metrics: Sensitivity, Specificity, PPV, and NPV are provided, which are key performance indicators for diagnostic tests.
Predicate Device: A predicate device (BinaxNOW PBP2a test) is listed, which is a common practice for demonstrating substantial equivalence for IVDs seeking regulatory clearance.

All of these factors align with the definition and characteristics of an In Vitro Diagnostic device.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

mecA XpressFISH® is a qualitative nucleic acid fluorescence in situ hybridization assay intended for the detection of mecA mRNA on smears from blood cultures that are positive for Staphylococcus aureus by the Staphylococcus QuickFISH™ BC assay.

The mecA XpressFISH® assay is indicated for use in conjunction with other laboratory tests and clinical data available to the clinician as an aid in the detection of mecA mRNA from methicillin-resistant S. aureus (MRSA) from patient positive blood cultures. The mecA XpressFISH® assay is not intended to monitor treatment for MRSA infections or for use with mixed cultures including those containing both S. aureus and coagulase negative staphylococci.

Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, epidemiological typing, and/or differentiation of mixed growth.

Product codes

MYI

Device Description

The mecA XpressFISH assay is a qualitative fluorescence in situ hybridization (FISH) assay which utilizes peptide nucleic acid (PNA) probes hybridizing to mecA messenger RNA (mRNA) on smears from blood cultures containing Staphylococcus aureus (SA). After the positive blood culture bottle is confirmed to have SA by Staphylococcus QuickFISH BC, an aliquot of the blood culture is incubated with media containing cefoxitin to induce mecA mRNA expression prior to mecA XpressFISH testing.

The assay consists of mecA mRNA inducing cefoxitin reagents, a fixation reagent, a hybridization reagent, a wash solution concentrate, coverslip mounting media and a microscope slide which has a sample well, and positive and negative control wells. Results are visualized and interpreted using fluorescence microscopy.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

blood cultures

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Description of the test set, sample size, data source, and annotation protocol:
The test set included 339 routine blood culture bottles that were determined to be positive for only Staphylococcus aureus by Staphylococcus QuickFISH BC. The source of the samples was routine blood cultures from seven clinical sites (6 US and 1 ex-US). The annotation protocol for MRSA identification was based on cefoxitin disk diffusion.

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Bench Testing:

Limit of Detection ("LoD"): Studied with three different MRSA strains (ATCC 33591, ATCC 43300, and NRS383) under simulated blood culture conditions. The LoD for each strain was 8.1x10^6 - 2.8x10^7 CFU/mL.
Analytic Reactivity (Inclusivity) and Analytic Specificity (Exclusivity):
- Inclusivity: Panel of 64 MRSA strains. 63/64 produced Green Positive results (one mecA-negative strain did not).
- Exclusivity: Panel of 30 MSSA, 40 other Staphylococcus species (CoNS), 36 other gram-positive organisms, and 20 other clinically relevant species. 29/30 MSSA produced Negative results, 1 mecA+ MSSA gave Green Positive. 6/40 CoNS produced Green Positive. 36/37 other Gram positive organisms tested Negative, Lactococcus lactis was Green Positive. Micrococcus luteus also produced weak Green Positive fluorescence. 1/19 other organisms (Candida parapsilosis) produced Green Positive.
Co-Infection: Tested MRSA with methicillin-sensitive staphylococci (S. aureus, S. epidermidis, S. simulans) at ~10^6 CFU/mL. No False Positive results from methicillin-sensitive staphylococci and no interference in MRSA detection.
Interfering Substances: Tested various substances including antibiotics, bilirubin, hemoglobin, triglycerides, SPS, and saponin. All MRSA samples produced Positive results; Linezolid caused weak fluorescence, noted as a limitation. All MSSA strains showed Negative results.
Compatible Blood Culture Media: Tested with 9 different blood culture media bottles from Becton Dickinson, bioMérieux, and Thermo Scientific. 100% overall agreement for MRSA Positive and MSSA Negative results.
Cross-contamination (Wash Step): Tested potential for cross-contamination during wash step using MRSA and MSSA slides. All MRSA samples were Green Positive (12/12, 100%) and all MSSA samples were Negative (3/3, 100%), indicating low risk of cross-contamination.
Cefoxitin Concentration: Tested at 2.5, 6.1, and 15 µg/mL with 20 MRSA and 3 MSSA strains. All MRSA produced Positive results (60/60; 100%) and all MSSA produced Negative results (9/9, 100%).
Cefoxitin Induction Time Range: Tested at 40, 45, and 50 minutes with 20 MRSA and 3 MSSA. All MRSA gave Positive results (60/60, 100%) and all MSSA produced Negative results (9/9, 100%).
Induction to Slide Preparation Interval: Tested immediately, 30, and 60 minutes after induction with 20 MRSA and 3 MSSA. All MRSA gave Positive results (60/60, 100%) and all MSSA produced Negative results (9/9, 100%).
Fixed Slide Stability Testing: Tested under prescribed storage conditions (room temperature for 1 hour, 2-8°C for 24 hours). All MRSA produced Positive results (158/158; 100%) and all MSSA produced Negative results (23/23, 100%).
Hybridization Time Range: Tested at 10, 15, and 20 minutes with 20 MRSA and 3 MSSA. All MRSA gave Positive results (60/60, 100%) and all MSSA produced Negative results (9/9, 100%).
Slide Wash Time Range: Tested at 10, 15, and 20 minutes with 20 MRSA and 3 MSSA. All MRSA gave Positive results (60/60, 100%) and all MSSA produced Negative results (9/9, 100%).
Age of Blood Culture at mecA XpressFISH Testing: Tested at

Regulation Number and Section

§ 866.1640 Antimicrobial susceptibility test powder.

(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).

Summary

0

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three human profiles facing to the right, with flowing lines connecting them.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

ADVANDX, INC. RON EISENWINTER DIRECTOR RA/CA 400 TRADECENTER SUITE 6990 WOBURN, MA 01801

October 10, 2014

Re: K140619

Trade/Device Name: mecA XpressFISH Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: II Product Code: MYI Dated: September 8, 2014 Received: September 9, 2014

Dear Mr. Eisenwinter:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

1

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Uwe Scherf -S for

Sally Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K140619

Device Name mecA XpressFISH

Indications for Use (Describe)

mecA XpressFISH® is a qualitative nucleic acid fluorescence in situ hybridization assay intended for the detection of mecA mRNA on smears from blood cultures that are positive for Staphylococcus aureus by the Staphylococcus QuickFISH™ BC assay.

The mecA XpressFISH® assay is indicated for use in conjunction with other laboratory tests and clinical data available to the clinician as an aid in the detection of mecA mRNA from methicillin-resistant S. aureus (MRSA) from patient positive blood cultures. The mecA XpressFlSH® assay is not intended to monitor treatment for MRSA infections or for use with mixed cultures including those containing both S. aureus and coagulase negative staphylococci.

Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, epidemiological typing, and/or differentiation of mixed growth.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary

510(k) Number: K140619

Applicant

AdvanDx, Inc. 400 TradeCenter, Suite 6990 Woburn, MA 01801

Contact Information:

Ronald K. Eisenwinter Director, Regulatory and Clinical Affairs AdvanDx, Inc. 400 TradeCenter, Suite 6990 Woburn, MA 01801 781-376-0009 extension 1027 Phone: Fax: 781-376-0111 E-mail: rke@advandx.com

Establishment Registration Number

3004080598

Manufacturer Establishment Number:

3003994627

Device Trade Name:

mecA XpressFISH (formerly mecA PNA FISH)

Device Common Name:

System, Test, Genotypic Detection, Resistant Markers, Staphylococcus Colonies

Device Classification:

AdvanDx mecA XpressFISH is a Class II device and is classified by FDA under 21 CFR §866.1640. Antimicrobial Susceptibility Test Powder. The Product Code is MYI.

4

Intended Use and Indications For Use

mecA XpressFISH® is a qualitative nucleic acid fluorescence in situ hybridization assay intended for the detection of mecA mRNA on smears from blood cultures that are positive for Staphylococcus aureus by the Staphylococcus QuickFISH™ BC assay.

The mecA XpressFISH® assay is indicated for use in conjunction with other laboratory tests and clinical data available to the clinician as an aid in the detection of mecA mRNA from methicillin-resistant S. aureus (MRSA) from patient positive blood cultures. The mecA XpressFISH® assay is not intended to monitor treatment for MRSA infections or for use with mixed cultures including those containing both S. aureus and coaqulase negative staphylococci.

Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, epidemiological typing, and/or differentiation of mixed growth.

Special conditions for use statement(s)

For Prescription Use only.

Special instrument requirements

Fluorescence microscope with appropriate filter and light source.

Device Description

The mecA XpressFISH assay is a qualitative fluorescence in situ hybridization (FISH) assay which utilizes peptide nucleic acid (PNA) probes hybridizing to mecA messenger RNA (mRNA) on smears from blood cultures containing Staphylococcus aureus (SA). After the positive blood culture bottle is confirmed to have SA by Staphylococcus QuickFISH BC, an aliquot of the blood culture is incubated with media containing cefoxitin to induce mecA mRNA expression prior to mecA XpressFISH testing.

The assay consists of mecA mRNA inducing cefoxitin reagents, a fixation reagent, a hybridization reagent, a wash solution concentrate, coverslip mounting media and a microscope slide which has a sample well, and positive and negative control wells. Results are visualized and interpreted using fluorescence microscopy.

Substantial Equivalence:

For the identification of mecA-mediated methicillin (Oxacillin) resistance in S. aureus, the mecA XpressFISH assay is substantially equivalent to the BinaxNOW PBP2a test (Alere, Maine, K090301), which detects the PBP2a protein responsible for methicillin resistance.

5

Similarities
Item	mecA XpressFISH
K140619	BinaxNOW PBP2a
K090301
Intended
Use	mecA XpressFISH ® is a
qualitative nucleic acid
fluorescence in situ
hybridization assay intended for
the detection of mecA mRNA
on smears from blood cultures
that are positive for
Staphylococcus aureus by the
Staphylococcus QuickFISH ™
BC assay.

The mecA XpressFISH ® assay
is indicated for use in
conjunction with other
laboratory tests and clinical
data available to the clinician
as an aid in the detection of
mecA mRNA from methicillin-
resistant S. aureus (MRSA)
from patient positive blood
cultures. The mecA
XpressFISH ® assay is not
intended to monitor treatment
for MRSA infections or for use
with mixed cultures including
those containing both S. aureus
and coagulase negative
staphylococci.

Sub-culturing of positive blood
cultures is necessary to recover
organisms for susceptibility
testing, epidemiological typing,
and/or differentiation of mixed
growth. | The BinaxNOW® PBP2a Test
is a qualitative, in vitro
immunochromatographic assay
for the rapid detection of
penicillin-binding protein 2a
(PBP2a) present in methicillin-
resistant Staphylococcus
aureus (MRSA). The test is
performed directly on blood
culture samples positive for S.
aureus .

Comparison Tables of Similarities and Differences

6

Similarities
Item	mecA XpressFISH
K140619	BinaxNOW PBP2a
K090301
Interpretation
Mode of
Operation	Manual	Same

Differences
Item	mecA XpressFISH
K140619	BinaxNOW PBP2a
K090301
Target
Analyte	mecA mRNA	PBP2a protein
Test Method	Molecular detection of gene
expression	Phenotypic detection of gene
expression
Technology	In situ hybridization of
fluorescently labeled peptide
nucleic acid (PNA) probe	Immunochromatography with
monoclonal antibodies that bind
to the penicillin binding protein
PBP2a
Sample
Preparation	Cefoxitin induced expression of
mecA expression	Recovery and washing of cells
by centrifugation, followed by
lysis
Controls	Integrated Positive and
Negative Controls to monitor
hybridization, washing and
result interpretation	Separate preparation of test
strip(s) for control organisms

Bench Testing

AdvanDx has conducted in-house bench testing of the mecA XpressFISH assay. The types of testing included limit of detection, analytic inclusivity, cross-reactivity, microbial interference, interfering substances (including different blood culture media), crosscontamination, tolerance, and reproducibility. Additionally, tests were conducted to validate the timing of each step of the testing procedure as well as the storage conditions of prepared slides.

The results of this testing verify that for the detection of mecA-mediated methicillin resistance in S. aureus in blood cultures, mecA XpressFISH is substantially equivalent to the BinaxNOW PBP2a predicate device.

7

Limit of Detection ("LoD")

Three different MRSA strains were used for the LoD study, MRSA ATCC 33591, ATCC 43300, and NRS383. Organisms were grown under simulated blood culture conditions.

The Limit of Detection was measured by serially diluting the MRSA strains in quadruplicate. The lowest readable concentration for each strain was re-tested in replicates of 20 and found to be 8.1x10 - 2.8x10 CFU/mL. This LoD is comparable to that of Staphylococcus QuickFISH and other slide based microbiological tests such as Gram Stain.

Analytic Reactivity (Inclusivity) and Analytic Specificity (Exclusivity)

The panel of organisms used to evaluate the analytical inclusivity (reactivity) of the mecA XpressFISH assay was comprised of 64 MRSA strains representing a broad spectrum of genotypes, clonal complexes, isolation dates, and locations. Of the 64 MRSA strains tested, only one, which is known not to carry the mecA gene, did not produce Green Positive results (mecC type).

For exclusivity (specificity), the panel included 30 strains of MSSA, 40 strains of other Staphylococcus species (i.e., coagulase-negative staphylococci [CoNS]), 36 strains of other gram-positive organisms, and 20 other clinically relevant species (i.e. gramnegatives and yeasts). Organisms were grown under simulated blood culture conditions. 29 of 30 MSSA produced Negative mecA XpressFISH results, while 1 MSSA, known to be mecA+, gave a Green Positive result. Six of the 40 other CoNS produced Green Positive results while the remaining 34 were Negative. Of the 37 other Gram positive organisms. 36 tested Negative. Lactococcus lactis was Green Positive. Subsequent additional analytical testing also produced weak Green Positive fluorescence with Micrococcus luteus. One of the 19 other orqanisms tested (Candida parapsilosis) produced a Green Positive result, while the other 18 were Negative. Because mecA XpressFISH is only indicated for use with blood cultures that contain Gram Positive Cocci in Clusters and which test Positive for S. aureus alone by Staphylococcus QuickFISH BC (i.e., pure cultures of S. aureus), the risk of False Positive results due to cross-reaction with other species is considered low.

Co-Infection

mecA XpressFISH is intended to be used with blood cultures of S. aureus as determined by Staphylococcus QuickFISH BC and is not intended to be used with mixed cultures identified either by Gram stain or Staphylococcus QuickFISH BC. Because of the inherent analytic sensitivity of slide based microbial tests and the variable rate of growth of microbes, there exists a possibility that a blood culture which appears to be positive solely for S. aureus by Gram stain and Staphylococcus QuickFISH BC is in fact a mixed culture (i.e., S. aureus and another species). In addition, should MRSA and MSSA occur together in the same blood culture, the culture would not be distinguishable as a mixed culture by either Gram stain or Staphylococcus QuickFISH BC. A microbial interference study was therefore conducted in order to

8

evaluate whether the presence of a non-MRSA organism would interfere with the detection of MRSA by mecA XpressFISH.

Testing was performed with simulated blood cultures to determine the impact of mixed populations of MRSA and MSSA or MRSA and coaqulase negative staphylococci on the mecA XpressFISH assay. Two strains of MRSA were tested in the presence of different "co-infecting" species of methicillin-sensitive staphylococci: S. aureus, S. epidermidis and S. simulans. The strains of MRSA were both tested near the previously determined LoD of the assay, which is ~10° CFU/mL. The other organisms were all tested at about 10° CFU/mL. No False Positive results were obtained from the methicillin-sensitive staphylococci and no interference was observed in detection of MRSA in the presence of the co-infecting species.

Interfering Substances

Testing of potential interfering substances was performed at the concentrations shown in the following Table. Two MRSA strains. ATC 43300 (MRSA 1) and NRS 674 (MRSA 2), and two MSSA strains, ATCC 29213 (MSSA 1) and ATCC 11632 (MSSA 2), were tested. All tests with MRSA produced Positive results, although only weak fluorescence was observed in the presence of Linezolid. Testing of samples from patients treated with Linezolid could therefore produce False Negative results. This is reflected as a limitation in the mecA XpressFISH Package Insert.

All MSSA strains showed Negative results.

9

| Substance | tion | MRSA 1 | MRSA 2 | MSSA |--------------------------------|---------- | Amoxicillin | 12 µg/mL | Clavulanate | 3 µg/mL | Sulbactam | 45 µg/mL | Ampicillin | 120 µg/mL | Clindamycin | 10 µg/mL | Daptomycin | 130 µg/mL | Ibuprofen | 50 µg/mL | Linezolid | 38 µg/mL | Oxacillin | 230 µg/mL | Vancomycin | 50 µg/mL | Amoxicillin and
Clavulanate | 12 µg/mL
3 µg/mL | Pos. | Pos. | Neg. | Sulbactam and
Ampicillin | 45 µg/mL
120 µg/mL | Pos. | Pos. | Neg. | Bilirubin | 150 µg/mL | Hemoglobin | ~30 mg/mL | Triglycerides | 3500 µg/mL | SPS | 0.04% | Saponin | ~0.2% Concentra-
1 | MSSA 2 |
-------------|-----------|-----------|--------|--------|
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Weak Pos. | Weak Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Neg. |
| Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |
| Pos. | Pos. | Neg. | Neg. |

Interference Testing Results

Compatible Blood Culture Media

An in-house study was conducted to assess the compatibility of mecA XpressFISH with certain of the most commonly used blood culture media of the three predominant blood culture systems. Testing was performed using multiple clinical strains of S. aureus representing a wide range of geographic and genotypic strain diversity.

In all, there were nine different blood culture media bottles tested. mecA XpressFISH testing for each MRSA produced a Positive result for all media types and each MSSA produced a Negative result for all media types, with an overall agreement of 100%. It is concluded that mecA XpressFISH is compatible with the nine commonly utilized blood culture media that were tested.

10

Manufacturer	Blood Culture System	Type of Media Bottle	Catalog Number
Becton Dickinson	BD BACTEC™	Plus Aerobic/F	442192
		Plus Anaerobic/F*	442193
		Standard/10 Aerobic/F*	442260
		Standard Anaerobic/F*	442191
		Lytic/10 Anaerobic/F	442265
		Peds Plus*	442194
bioMérieux	BacT/ALERT®	SA-Standard Aerobic	259789
		SN-Standard
Anaerobic*	259790

Thermo Scientific	VersaTREK	REDOX 1 aerobic*	7102-44

Blood Culture Media Types Tested

*Clinical performance with mecA XpressFISH not established.

Cross-contamination (Wash Step)

According to the instructions for use, mecA XpressFISH slides can be washed in batches of up to five slides following the hybridization step. This is the only step in the mecA XpressFISH procedure where slides prepared from different samples (patients) are present and exposed together to a common reagent and where they might become cross-contaminated. AdvanDx conducted an in-house study with the mecA XpressFISH assay to assess the potential for cross-contamination during the wash step leading to False Positive results.

A well characterized mecA positive MRSA strain (NRS 383) and a strain of MSSA (ATCC BAA 1718) were used for testing. For each run, a set of four MRSA slides and one MSSA slide was prepared from simulated blood cultures at >10° CFU/mL. Three sets of five slides were processed through the hybridization step according to the mecA XpressFISH procedure and each slide set was then placed into a slide holder for the wash step. The placement of the MSSA slide relative to the four MRSA slides within the holder was varied between sets (i.e., the MSSA slide within a set was placed at a different middle or outside position relative to the four MRSA slides within the holder). The slide sets were each then washed according to the mecA XpressFISH procedure. and the slides were mounted and examined by fluorescence microscopy. All MRSA samples were Green Positive (12/12, 100%) and all MSSA samples were Negative (3/3, 100%) with no Green Positive organisms found in the MSSA sample wells (or Internal Negative Control wells). The results verify that cross-contamination of slides is unlikely to occur when up to five slides are washed together.

Cefoxitin Concentration

It was established during the mecA XpressFISH product development that a cefoxitin concentration of between 2.5 and 15 ug/mL in TSB is optimal for induction of the mecA gene within 40-50 min. at 35°C. AdvanDx conducted an in-house study to verify the functional range of cefoxitin concentration in TSB for the mecA XpressFISH assay. A

11

panel of 20 diverse MRSA and three MSSA strains were grown under simulated blood culture conditions. The mecA XpressFISH assay was then conducted with each sample where the cefoxitin concentration in TSB was set at three different levels: 2.5ug/mL, 6.1µg/mL and 15µg/mL. All 20 of the MRSA tested under the three cefoxitin concentrations for the induction step produced Positive mecA XpressFISH test results (60/60; 100%) and all three MSSA produced Negative test results (9/9, 100%). The results verify that a cefoxitin concentration range of 2.5-15 ug/mL is suitable for induction of mecA mRNA expression.

Cefoxitin Induction Time Range

Exposure of MRSA to cefoxitin (or other methicillin-type drugs) induces the production of mecA mRNA. As part of the product development for mecA XpressFISH, it was determined that 40 to 50 minutes of drug exposure is required to activate mecA gene transcription for MRSA strains that do not express (or only weakly express) mecA mRNA in the absence of drug exposure. In order to verify this time range, AdvanDx conducted an in-house study with the mecA XpressFISH assay and a panel of wellcharacterized MRSA strains to assess test performance within the prescribed time range. A panel of 20 MRSA and three MSSA were tested at each of three time points: 40, 45 and 50 minutes. All 20 of the MRSA gave a Positive result for mecA XpressFISH at each of the three time points tested (60/60, 100%). All three of the MSSA produced a Negative result for each time point (9/9, 100%). The results verify that a 40-50 min. induction time is suitable for induction of mecA mRNA.

Induction to Slide Preparation Interval

During the design of mecA XpressFISH it was determined that users wished to have flexibility in the timing between completion of the cefoxitin induction step and preparation of smears from the induced culture. AdvanDx conducted an in-house study to assess whether a delay of up to one hour between induction and slide preparation would affect the performance of mecA XpressFISH. A panel of 20 MRSA and 3 MSSA were grown under simulated blood culture conditions. Following the induction step. slides were prepared immediately and then at 30 and 60 minutes. Induced cultures were stored at room temperature prior to slide preparation. All 20 of the MRSA gave a Positive test result for mecA XpressFISH at the three time points tested (60/60, 100%) and the three MSSA produced Negative results (9/9, 100%). The results verify that slides may be prepared for up to one hour after the completion of the induction step.

Fixed Slide Stability Testing

During the design of the mecA XpressFISH assay it was determined that users wished to have flexibility in the timing between completion step and the start of the hybridization step of the assay procedure. According to the instructions for use, fixed slides may be stored under the following conditions prior to the hybridization step:

. Store mecA XpressFISH control slides in their original, individually sealed pouches at 2-8°C. Slides must be used immediately after breaking pouch seal. Do not use slides after the expiration date.

12

. Fixed mecA XpressFISH smears should be hybridized within 5 minutes following fixation and may be left on the slide warmer at 55 ± 1°C for up to 5 minutes before addition of the hybridization reagent (mecA PNA).
- Prepared smears may be stored at room temperature for up to 1 hour prior to testing or o may be stored at 2-8 °C for up to 24 hours before testing.
Note: If smears were stored after fixation at 2-8°C or room temperature they must be placed on . the slide warmer for approximately 5 minutes at 55 ± 1℃ before adding the hybridization reagents.

AdvanDx conducted an in-house study of the mecA XpressFISH assay to assess test performance within the prescribed fixed slide storage times and conditions. Multiple clinically relevant strains of S. aureus were tested under the described conditions. All MRSA tested under the various storage conditions and times produced Positive mecA XpressFISH test results (158/158; 100%) and all three MSSA produced Negative test results (23/23, 100%). The results verify that following the fixation step, slides may be stored and processed according to the instructions for use, without affecting test performance.

Hybridization Time Range

During the design of the mecA XpressFISH assay, it was determined that users would need to have flexibility in the duration of the hybridization step in order to accommodate batch processing of small numbers of slides and for other reasons. According to the instructions for use, the hybridization for mecA XpressFISH can be performed within 10 to 20 minutes. AdvanDx conducted an in-house study to assess test performance within this prescribed time range. A panel of 20 MRSA and three MSSA were tested at each of three time points (10, 15, and 20 minutes of hybridization). The twenty MRSA gave a Positive test result for mecA XpressFISH at the three time points tested (60/60. 100%) and the three MSSA produced Negative test results (9/9, 100%). The results verify that the hybridization time of between 10 and 20 minutes is suitable.

Slide Wash Time Range

According to the instructions for use, mecA XpressFISH slides may be washed for between 10 to 20 minutes at 57°C following the hybridization step. An AdvanDx inhouse study was conducted with the mecA XpressFISH assay to assess test performance within this prescribed time range. A panel of 20 MRSA and three MSSA were tested at each of three time points: 10, 15, and 20 minutes. The twenty MRSA gave a Positive test result for mecA XpressFISH at the three time points tested (60/60, 100%) and the three MSSA produced Negative test results (9/9, 100%). The results verify that a slide wash time of between 10 and 20 minutes is suitable.

Age of Blood Culture at mecA XpressFISH Testing

ldeally in the clinical setting, mecA XpressFISH should be performed as soon as possible after blood culture bottle positivity and the completion of Staphylococcus QuickFISH BC testing. However, the elapsed time from blood culture positivity to mecA XpressFISH testing could vary from lab to lab, depending on such factors as laboratory staffing, reporting policies, and time of day at which bottles signal Positive. Hence, the age of a Positive blood culture bottle at the time of mecA XpressFISH testing could be

13

as little as mecA XpressFISH
Positive | 151 | 11 | PPV
99.3%(151/152)
95% CI
(96.4-99.9) |
| mecA XpressFISH
Negative | 22 | 185 | NPV
98.9%(185/187)
95% CI
96.2-99.7 |
| N=339 | Sensitivity
98.7% (151/153)
95%CI
(95.4-99.6) | Specificity
99.5% (185/186)
95% CI
(97.0-99.9) | |

False Positive mecA (weak Green Positive); Negative upon repeat testing. Cefoxitin disk=28 mm. 2Two False Negative mecA: For one, repeat testing was Negative, and for the other it was Positive (weak Green Positive). Cefoxitin disk diffusion results were19mm and 11mm, respectively.

An analysis of the results of the clinical study by site and type of culture medium is presented in the table below.

| Bottle Type | Site | Methicillin
Resistant
(mecA+) | Methicillin
Susceptible
(mecA-) | Total
(%; 95% CI) |
|--------------------------------|----------------------------|-------------------------------------|---------------------------------------|------------------------------|
| BACTEC Plus Aerobic/F | A | 2/2 | 12/12 | 14/14
(100) |
| | B | 18/19 | 17/17 | 35/36
(97.2) |
| | C | 7/7 | 18/19 | 25/26
(96.2) |
| | D | 7/7 | 14/14 | 21/21
(100) |
| | E | 19/19 | 19/19 | 38/38
(100) |
| | Total
(%; 95% CI) | 53/54
(98.1; 90.2-99.7) | 80/81
(98.8; 93.3-99.8) | 133/135
(98.5; 94.8-99.6) |
| BACTEC Lytic/10
Anaerobic/F | A | 7/7 | 10/10 | 17/17
(100) |
| | B | 10/10 | 17/17 | 27/27
(100) |
| | C | 10/10 | 14/14 | 24/24
(100) |
| | D | 19/19 | 4/4 | 23/23
(100) |
| | E | 13/14 | 13/13 | 26/27
(96.3) |
| Total
(%; 95% CI) | 59/60
(98.3; 91.1-99.7) | 58/58
(100; 93.8-100) | 117/118
(99.2; 95.4-99.9) | |

16

| Bottle Type | Site | Methicillin
Resistant
(mecA+) | Methicillin
Susceptible
(mecA-) | Total
(%; 95% CI) |
|-------------------------------------|--------------------------|-------------------------------------|---------------------------------------|------------------------------|
| BACTEC Peds Plus | B | 1/1 | 1/1 | 2/2
(100) |
| | C | 2/2 | 5/5 | 7/7
(100) |
| | D | 0 | 1/1 | 1/1
(100) |
| | Total
(%; 95% CI) | 3/3
(100; 43.9-100) | 7/7
(100; 64.6-100) | 10/10
(100; 72.3-100) |
| BACTEC Plus
Anaerobic/F | B [Total]
(%; 95% CI) | 7/7
(100; 64.6-100) | 5/5
(100; 56.6-100) | 12/12
(100; 75.8-100) |
| BACTEC Standard/10
Aerobic/F | D [Total]
(%; 95% CI) | 0 | 1/1
(100; 20.7-100) | 1/1
(100; 20.7-100) |
| | Total
(%; 95% CI) | 122/124
(98.4; 94.3-99.6) | 151/152
(99.3; 96.4-99.9) | 273/276
(98.9; 96.9-99.6) |
| BACTEC All Media | F | 24/24 | 18/18 | 42/42
(100) |
| | G | 1/1 | 8/8 | 9/9
(100) |
| | | Total
(%; 95% CI) | 25/25
(100; 86.7-100) | 26/26
(100; 87.1-100) |
| BacT/ALERT
SA Standard Aerobic | F | 4/4 | 2/2 | 6/6
(100) |
| | G | 0 | 6/6 | 6/6
(100) |
| | | Total
(%; 95% CI) | 4/4
(100; 51.0-100) | 8/8
(100; 67.6-100) |
| BacT/ALERT
SN Standard Anaerobic | Total
(%; 95% CI) | 29/29
(100; 88.3-100) | 34/34
(100; 89.9-100) | 63/63
(100; 94.2-100) |
| BacT/ALERT All Media | Total
(%; 95% CI) | 29/29
(100; 88.3-100) | 34/34
(100; 89.9-100) | 63/63
(100; 94.2-100) |

Conclusion

It is concluded from the data presented above, that the identification of mecA-mediated methicillin resistance in Staphylococcus aureus by the mecA XpressFISH assay from S. aureus positive blood culture bottles as identified by Staphylococcus QuickFISH BC is substantially equivalent to identification a previously cleared predicate method and does not raise new types of safety or effectiveness questions when used as labelled.